147 related articles for article (PubMed ID: 20233165)
1. Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril.
Watermeyer JM; Kröger WL; O'Neill HG; Sewell BT; Sturrock ED
Biochem J; 2010 Apr; 428(1):67-74. PubMed ID: 20233165
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor.
Denti P; Sharp SK; Kröger WL; Schwager SL; Mahajan A; Njoroge M; Gibhard L; Smit I; Chibale K; Wiesner L; Sturrock ED; Davies NH
Eur J Pharm Sci; 2014 Jun; 56():113-9. PubMed ID: 24561703
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme.
Nchinda AT; Chibale K; Redelinghuys P; Sturrock ED
Bioorg Med Chem Lett; 2006 Sep; 16(17):4616-9. PubMed ID: 16784843
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
5. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.
Sharp S; Poglitsch M; Zilla P; Davies NH; Sturrock ED
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1149-58. PubMed ID: 25757657
[TBL] [Abstract][Full Text] [Related]
7. Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors.
Polakovičová M; Jampílek J
Med Chem; 2019; 15(6):574-587. PubMed ID: 31084594
[TBL] [Abstract][Full Text] [Related]
8. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380.
Corradi HR; Chitapi I; Sewell BT; Georgiadis D; Dive V; Sturrock ED; Acharya KR
Biochemistry; 2007 May; 46(18):5473-8. PubMed ID: 17439247
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex.
Natesh R; Schwager SL; Sturrock ED; Acharya KR
Nature; 2003 Jan; 421(6922):551-4. PubMed ID: 12540854
[TBL] [Abstract][Full Text] [Related]
10. Probing the basis of domain-dependent inhibition using novel ketone inhibitors of Angiotensin-converting enzyme.
Watermeyer JM; Kröger WL; O'Neill HG; Sewell BT; Sturrock ED
Biochemistry; 2008 Jun; 47(22):5942-50. PubMed ID: 18457420
[TBL] [Abstract][Full Text] [Related]
11. Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.
Arendse LB; Cozier GE; Eyermann CJ; Basarab GS; Schwager SL; Chibale K; Acharya KR; Sturrock ED
J Med Chem; 2022 Feb; 65(4):3371-3387. PubMed ID: 35113565
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensin-converting enzyme.
Binevski PV; Sizova EA; Pozdnev VF; Kost OA
FEBS Lett; 2003 Aug; 550(1-3):84-8. PubMed ID: 12935891
[TBL] [Abstract][Full Text] [Related]
13. Kinetic probes for inter-domain co-operation in human somatic angiotensin-converting enzyme.
Skirgello OE; Binevski PV; Pozdnev VF; Kost OA
Biochem J; 2005 Nov; 391(Pt 3):641-7. PubMed ID: 16033330
[TBL] [Abstract][Full Text] [Related]
14. Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.
Redelinghuys P; Nchinda AT; Chibale K; Sturrock ED
Biol Chem; 2006 Apr; 387(4):461-6. PubMed ID: 16606345
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb).
Sturrock ED; Lubbe L; Cozier GE; Schwager SLU; Arowolo AT; Arendse LB; Belcher E; Acharya KR
Biochem J; 2019 May; 476(10):1553-1570. PubMed ID: 31072910
[TBL] [Abstract][Full Text] [Related]
16. ACE-domain selectivity extends beyond direct interacting residues at the active site.
Cozier GE; Lubbe L; Sturrock ED; Acharya KR
Biochem J; 2020 Apr; 477(7):1241-1259. PubMed ID: 32195541
[TBL] [Abstract][Full Text] [Related]
17. Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme.
Larmuth KM; Masuyer G; Douglas RG; Schwager SL; Acharya KR; Sturrock ED
FEBS J; 2016 Mar; 283(6):1060-76. PubMed ID: 26748546
[TBL] [Abstract][Full Text] [Related]
18. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme.
Perich RB; Jackson B; Johnston CI
Eur J Pharmacol; 1994 Feb; 266(3):201-11. PubMed ID: 8174603
[TBL] [Abstract][Full Text] [Related]
19. Simulated interactions between angiotensin-converting enzyme and substrate gonadotropin-releasing hormone: novel insights into domain selectivity.
Papakyriakou A; Spyroulias GA; Sturrock ED; Manessi-Zoupa E; Cordopatis P
Biochemistry; 2007 Jul; 46(30):8753-65. PubMed ID: 17605472
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design.
Corradi HR; Schwager SL; Nchinda AT; Sturrock ED; Acharya KR
J Mol Biol; 2006 Mar; 357(3):964-74. PubMed ID: 16476442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
